Global Stroke Care Continuum Research Report 2023: Trends, Growth Opportunities, and Forecasts 2023-2027 with 2022 as the Base Year
August 04, 2023 09:33 ET
|
Research and Markets
Dublin, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Stroke Care Continuum: Trends, Growth Opportunities, and Forecasts" report has been added to ResearchAndMarkets.com's offering. This study...
Neurocritical AI solution to be deployed into A&E at Milton Keynes University Hospital NHS Foundation Trust
August 01, 2023 03:15 ET
|
Blackford
EDINBURGH, Scotland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blackford, the pioneering strategic AI platform and solutions provider, has partnered with Qure.ai, a leading provider of artificial...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
June 26, 2023 20:25 ET
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
June 26, 2023 07:00 ET
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
June 05, 2023 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
June 05, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
May 31, 2023 09:19 ET
|
Pharmazz, Inc.
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 04, 2023 10:43 ET
|
Tiziana Life Sciences Ltd.
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...